Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants.
Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M. Belnoue E, et al. Among authors: walchli s. Mol Ther. 2016 Sep;24(9):1675-85. doi: 10.1038/mt.2016.134. Epub 2016 Jul 5. Mol Ther. 2016. PMID: 27377043 Free PMC article.
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM. Dillard P, et al. Among authors: walchli s. Mol Ther. 2021 Mar 3;29(3):1199-1213. doi: 10.1016/j.ymthe.2020.11.019. Epub 2020 Nov 17. Mol Ther. 2021. PMID: 33212301 Free PMC article.
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.
Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM. Maggadottir SM, et al. Among authors: walchli s. Mol Ther. 2024 Apr 6:S1525-0016(24)00225-9. doi: 10.1016/j.ymthe.2024.04.009. Online ahead of print. Mol Ther. 2024. PMID: 38582964 Free article.
Unpredicted phenotypes of two mutants of the TcR DMF5.
Tadesse FG, Mensali N, Fallang LE, Walseng E, Yang W, Olweus J, Wälchli S. Tadesse FG, et al. Among authors: walchli s. J Immunol Methods. 2015 Oct;425:37-44. doi: 10.1016/j.jim.2015.06.006. Epub 2015 Jun 14. J Immunol Methods. 2015. PMID: 26079729
A TCR-based Chimeric Antigen Receptor.
Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S. Walseng E, et al. Among authors: walchli s. Sci Rep. 2017 Sep 6;7(1):10713. doi: 10.1038/s41598-017-11126-y. Sci Rep. 2017. PMID: 28878363 Free PMC article.
Long-term surviving cancer patients as a source of therapeutic TCR.
Inderberg EM, Wälchli S. Inderberg EM, et al. Among authors: walchli s. Cancer Immunol Immunother. 2020 May;69(5):859-865. doi: 10.1007/s00262-019-02468-9. Epub 2020 Jan 8. Cancer Immunol Immunother. 2020. PMID: 31915853 Free PMC article. Review.
Sympathetic improvement of cancer vaccine efficacy.
Inderberg EM, Wälchli S. Inderberg EM, et al. Among authors: walchli s. Hum Vaccin Immunother. 2020 Aug 2;16(8):1888-1890. doi: 10.1080/21645515.2019.1703456. Epub 2020 Jan 24. Hum Vaccin Immunother. 2020. PMID: 31977269 Free PMC article.
91 results